ArticleCell death discovery2026
Inhibition of TGM2 enhances cisplatin sensitivity in MSH2-deficient bladder cancer.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
MSH2 (mutS homolog 2) gene, a key component of the DNA mismatch repair system, garners significant attention for its influence on cancer progression and prognosis. Loss of MSH2 protein decreases the chemosensitivity of bladder cancer (BCa) to cisplatin (CDDP). However, precision therapeutic strategy based on MSH2 deficiency is not available clinically. Herein, we reported that knockout of MSH2 reduced the sensitivity of BCa to CDDP. Importantly, GK921, a TGM2-specific inhibitor, increased tumor cell killing by CDDP in MSH2-deficient BCa. GK921 also promoted the chemotherapeutic sensitivity of Msh2-knockout mice to CDDP. In addition, Hi-C analysis indicated that MSH2 deficiency rewired chromatin accessibility of the TGM2 promoter region, leading to recruit more transcription factors. Accordingly, we found that the enrichment levels of transcription factor AP-1 in TGM2 promoter region were increased in MSH2-knockout BCa cells, thereby promoting the expression of TGM2 transcriptionally. This study uncovers that CDDP effectiveness depends on TGM2 levels in MSH2-deficient BCa and that the combination of CDDP with TGM2 inhibition may represent a promising therapeutic strategy for MSH2-deficient BCa patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.